Novartis boosts involvement in anti-Covid treatment
Swiss pharmaceutical company Novartis says it has signed a deal with biotech firm Molecular Partners to develop, manufacture and commercialise an anti-Covid-19 treatment drug.
The Basel-based company said the option and licence agreement was aimed at boosting a programme consisting of two antiviral therapeutic candidates, MP0420 and MP0423.
“It is clear that this pandemic calls for not just scientific solutions, but also for collaboration between companies to provide treatments in an area of high unmet need,” Novartis said in a statement publishedExternal link on Wednesday.
Molecular Partners will be responsible for the conduct of phase 1 and 2 trials.
Under the terms of the agreement, Molecular Partners will receive an initial payment of CHF60 million ($66.1 million). If Novartis takes up the option to both drugs, it will pay another CHF150 million to the biotech company.
In August, the Swiss government signed an agreement with Molecular Partners for priority access to a drug being developed to treat those severely ill with Covid-19.
It gives Switzerland access to the first 200,000 doses of the medicine, as well as up to three million further doses when requested.
University of Lausanne calls for end to pro-Palestine sit-in
This content was published on
The pro-Palestinian occupation continues at the University of Lausanne (UNIL). On Monday evening, a group of students refused to agree to the deadline set by the rectorate.
Ukraine peace conference should include Russia, says Chinese ambassador
This content was published on
China supports a peace conference on the Ukraine war that would see equal participation of all parties, says Chinese Ambassador to Russia Zhang Hanhui.
This content was published on
A majority of Swiss citizens have open attitudes towards various infertility treatments, including even egg donation, which is currently prohibited.
Reports of Swiss cyber fraud almost doubled in six months
This content was published on
The head of the new Federal Office for Cybersecurity (FOC), Florian Schütz, has presented a new strategy after just over four months in office.
Ecological status of Swiss streams insufficient according to study
This content was published on
Pesticide use and obstructions of waterways have a particularly negative impact on sensitive organisms, completely absent in 70% of streams analysed.
Train line between Brig and Domodossola interrupted
This content was published on
One day after a derailment approximately 15 kilometres from the Swiss border, BLS is running buses for passengers between Preglia and Domodossola, in Italy.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Roche bids to co-develop potential oral Covid-19 treatment
This content was published on
The Basel-based company has partnered with Atea Pharmaceuticals to develop, manufacture and distribute the latter’s oral anti-Covid-19 treatment.
Switzerland fast-tracks antiviral medication against Covid-19
This content was published on
Swissmedic, the agency that oversees the use of medicaments in Switzerland, took days to fast-track approval of the drug, which is produced under the brand name Veklury by US biopharmaceutical company Gilead Sciences. The application for its extended use was only received on Monday. It can now be used for a limited period of time to…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.